Related by context. All words. (Click for frequent words.) 81 granted Orphan Drug 76 granted orphan 70 granted orphan medicinal 68 Granted Orphan Drug 65 Orphan Drug designations 64 Receives Orphan Drug 63 highly purified pasteurized 63 small molecule Hedgehog 63 oral isoform selective HDAC 62 formerly LymphoStat B 62 targeted radiotherapeutic 62 Receives Fast Track 61 BENLYSTA TM 61 methylnaltrexone bromide 61 Vitrasert R 61 Orphan Drug status 61 orphan medicinal product 61 albiglutide 60 oral dihydropyrimidine dehydrogenase DPD 60 Fast Track Status 60 novel histone deacetylase 59 Panzem R 59 personalized cellular immunotherapy 59 orally administered inhibitor 59 investigational humanized monoclonal antibody 59 Grants Orphan Drug 59 investigational oral inhibitor 59 substantially excreted 59 novel DACH platinum 59 peripherally acting 59 candidates Azedra TM 59 Sodium oxybate 59 mitogen activated ERK kinase 59 prokinetic agent 58 AAG geldanamycin analog 58 investigational pharmacologically unique 58 PNP inhibitor 58 class anticancer quinolone 58 virus HCV protease inhibitor 58 candidates Azedra 58 severe gastroparesis 58 use transdermal sumatriptan 58 delivers fluocinolone acetonide FA 58 AQD class 58 lead molecular radiotherapeutic 58 pseudobulbar affect PBA 58 oral prodrug 57 MKC# MKC# PP 57 IMiDs ® 57 selective modulator 57 Zorbtive TM 57 oral nucleoside analogue 57 zolpidem tartrate sublingual tablet 57 IMiDs R 57 XL# anticancer compounds 57 molecular imaging radiopharmaceutical 57 CYP#A# isoenzyme 57 Pathway Inhibitor 57 Intravenous Human 57 FDA Orphan Drug 57 BYETTA ® 57 sapropterin dihydrochloride 57 receptor tyrosine kinase inhibitor 57 GTC recombinant form 57 delivers sumatriptan 57 Solazed ™ 57 metastatic HER2 negative 57 TNF Tumor Necrosis Factor 57 pregabalin Lyrica 57 Pruvel TM 57 candidate ridaforolimus 57 IgG1 monoclonal antibody 57 Epratuzumab 57 topically applied SEPA 57 refractory chronic lymphocytic 57 RANK Ligand inhibitor 57 essential thrombocythemia ET 57 BiovaxID TM 57 delivery polymer matrix 57 Bezielle 57 Receives Orphan Drug Designation 57 GW# [003] 56 evaluating tivozanib 56 BENLYSTA ® 56 mild vasodilator 56 orphan drug 56 Orphan Medicinal Product 56 product candidate Lpathomab 56 Hsp# Inhibitor 56 Pafuramidine 56 Meets Primary Endpoint 56 Solzira TM 56 CCR5 antagonist 56 Somatuline Depot 56 Arzerra ofatumumab 56 ankylosing spondylitis psoriatic arthritis 56 Belimumab 56 vitreoretinal disorders 56 Tibotec Therapeutics division 56 histone deacetylase HDAC inhibitor 56 GTC recombinant human 56 Orphan Drug 56 acyclovir Lauriad R 56 Elagolix 56 sitaxsentan sodium 56 Besivance 56 tiapamil 56 Nasdaq PGNX today 56 MTP inhibitor 56 Initiates Phase III 56 markets HP Acthar 56 coagulation factor VIIa 56 PROVENGE ® 56 approved incretin mimetic 56 dasatinib Sprycel ® 56 Amigal TM 56 systemic juvenile idiopathic 56 bile duct tumor 56 JAK2 Inhibitor 56 therapy PBRT system 56 Onalta ™ 56 label Lipofen R 56 dextromethorphan quinidine 56 humanized monoclonal antibody 55 Personalized Immunotherapy 55 REMOXY POSIDUR ELADUR 55 Genasense ® oblimersen 55 mesylate tablets approved 55 Kuvan R 55 substrates inhibitors 55 histamine dihydrochloride 55 BCG refractory carcinoma 55 PEGylated Fab fragment 55 huC# DM4 55 Tanespimycin 55 class mGluR5 inhibitor 55 Pegloticase 55 Application BLA 55 Onalta 55 Orphan Drug designation 55 Albugon 55 opioid induced constipation OIC 55 therapeutically inactive prodrug 55 diagnosed Ph + 55 Bafetinib 55 Fast Track designations 55 Lambert Eaton Myasthenic 55 Opterone R 55 initiated Phase Ib 55 ocular formulation 55 CYP#A# CYP#D# 55 Iluvien ® 55 candidate Zenvia 55 ALN TTR 55 Daclizumab 55 candidate Zelrix 55 acetonide FA 55 Eraxis 55 human IgG1 monoclonal 55 novel VDA molecule 55 Kosan dependence 55 apricitabine ATC 55 erlotinib Tarceva ® 55 DexaSite 55 Alfacell proprietary ribonuclease 55 CYT# potent vascular disrupting 55 LymphoStat B belimumab 55 metaglidasen 55 autologous cellular immunotherapy 55 diarrhea predominant irritable 55 accumulate preferentially 55 Atripla combines 54 Preclinical studies suggest 54 4SC AG ISIN DE# 54 FOLOTYN ® 54 Archexin 54 RELISTOR ® 54 novel L DOS# 54 Syndrome LEMS 54 ALN PCS 54 Liprotamase 54 human C1 inhibitor 54 mertansine 54 post herpetic neuralgia PHN 54 Eprodisate KIACTA TM 54 lintuzumab SGN 54 Aflibercept 54 EGFR monoclonal antibody 54 chimeric monoclonal antibody 54 Zenvia ™ 54 Application MAA 54 Voreloxin 54 relapsed leukemia 54 protein tyrosine phosphatase 1B 54 outlicensed 54 recombinant biopharmaceutical 54 Silodosin 54 markets Gelclair R 54 MOVIPREP R 54 targeted antifolate 54 oral isotype selective HDAC 54 5 HT2A inverse 54 forodesine hydrochloride 54 HCV polymerase 54 potent inhibitor 54 Triphendiol 54 FDA Accepts 54 STEDESA 54 CDK cyclin dependent 54 OXIGON TM 54 sorafenib tablets 54 IMPDH inhibitor 54 sodium glucose cotransporter 54 anticancer compound 54 using VIAdel TM 54 HCV protease 54 ABL inhibitor 54 Anti VEGF 54 rheumatoid arthritis thrombocytopenia 53 alefacept 53 Staphylococcus aureus Immune Globulin 53 potently inhibit 53 Orphan Designation 53 nephropathic cystinosis 53 IMiD 53 Vidaza azacitidine 53 Troxatyl TM 53 proteasome inhibitor 53 R sorafenib tablets 53 Ceflatonin R 53 investigational compound 53 pediatric Crohn disease 53 Fibrillex TM 53 HCV NS3 protease 53 novel emulsion formulation 53 ketolide antibiotic 53 Plecanatide 53 daily injectable lipoglycopeptide 53 MEK Inhibitor 53 Priority Review 53 Triapine 53 COLAZAL R 53 Xanafide 53 liposomal formulation 53 Initiate Clinical Trial 53 product platforms AZX# 53 NEBIDO R 53 Milnacipran 53 Tumour Vascular Disrupting Agent 53 KNS # 53 equine osteoarthritis 53 investigational monoclonal antibody 53 cutaneous T 53 IAP inhibitor 53 RhuDex ® 53 polysaccharide polymer 53 Maribavir 53 5 HT3 antagonist 53 OMAPRO ™ 53 subsidiaries visit http:/www.apricusbio.com 53 candidate Zemiva TM 53 Rhucin ® recombinant 53 Sudhir Agrawal D.Phil 53 pathophysiological effects 53 orally bioavailable 53 liver resection surgeries 53 Oracea TM 53 R Abelcet 53 Serdaxin ® 53 STELARA TM 53 IL# PE#QQR 53 IMiDs ® compound 53 oral NKTR 53 Gamunex C 53 B lymphocyte stimulator 53 Peginterferon alfa 2b 53 MAGE A3 ASCI 53 Elvitegravir 53 Homspera TM 53 R DepoCyt 53 Pivotal Phase III 53 Fx #A 53 Marqibo TM 53 generation purine nucleoside 53 injectable investigational 53 valtorcitabine 53 anti CD3 monoclonal 53 immunotherapeutic agent 53 Fast Track designation 52 Project QTDP 52 torsemide ER 52 HCV protease inhibitor 52 Febuxostat 52 adalimumab Humira 52 oral immunomodulatory 52 Attains Gold Certified Partner 52 systemically administered 52 novel therapeutic antibodies 52 lead compound ISA# 52 Tarceva TM 52 thrombin component 52 ZALBIN 52 anti amnesic 52 HuMax TAC 52 ATRA IV 52 vinca alkaloid 52 Familial Adenomatous Polyposis FAP 52 factors ZFP TFs 52 gave Makena orphan 52 HP Acthar Gel repository 52 daily Glumetza TM 52 Proquin XR 52 thetreatment 52 Alitretinoin 52 Orphan Status 52 vaccine RiVax TM 52 reslizumab 52 AVASTIN 52 buccal tablets 52 TORISEL TM 52 Fast Track Designation 52 Taliglucerase alfa 52 ATryn ® GTC recombinant 52 MT# MEDI 52 Emezine R 52 Lpl Financial Corp 52 humanized anti 52 Benlysta belimumab 52 Cimzia certolizumab pegol 52 Ostabolin C TM 52 acting muscarinic antagonist 52 Recombinant interferon alpha 52 directed radiotherapeutic antibody 52 Orphan Drug Designation 52 ADP receptor antagonist 52 AzaSite Plus 52 Clevudine 52 AcryMed Incorporated 52 polymerase inhibitors 52 diagnosed chronic myeloid 52 Xyfid TM 52 JAK inhibitor 52 rusalatide acetate 52 Injection r 52 PORxin TM platforms 52 DG# compounds targeting 52 administered subcutaneously 52 Dapagliflozin 52 www.nanoviricides.com 52 cell lymphoma CTCL 52 CML CP 52 topical anti infective 52 hypoxia activated prodrug 52 5 lipoxygenase inhibitor 52 thalidomide Thalomid 52 leading oral taxane 52 Orphan Drug Status 52 gastro intestinal inflammation 52 DORIBAX 52 RTP #i 52 Tezampanel 52 Nutra Pharma wholly owned 52 Fodosine 52 orally administered 52 HQK 52 candidate deforolimus 52 Ambrisentan 52 delta opioid receptor 52 genetically engineered recombinant protein 52 Refractory Peripheral T 52 Drug Eluting Stent System 52 Dacetuzumab 51 carcinoid syndrome 51 pancreatic enzyme replacement 51 Nicotine Conjugate Vaccine 51 BLP# Liposome Vaccine 51 created ZFP transcription 51 forodesine 51 Ixabepilone 51 Prodarsan ® 51 Acetavance TM 51 Simulect 51 Clofarabine 51 relapsed myeloma 51 Onalta TM 51 Panflu TM Sinovac 51 Argatroban 51 Annamycin 51 Factor VIIa 51 Orphan medicinal 51 ALVESCO R 51 rilonacept 51 XYOTAX TM 51 UPLYSO 51 peptidic compound 51 imatinib Gleevec ® 51 Troxatyl 51 Firdapse TM amifampridine phosphate 51 aerosolized AAT 51 JAK2 inhibitor 51 DosePro TM 51 Pralatrexate 51 ospemifene 51 PHARMACEUTICALS INDUSTRY 51 RDEA# potent 51 Rebif ® 51 nucleoside analog 51 mesylate 51 Friedreich Ataxia FRDA 51 triggers apoptosis programmed 51 DURIN TM 51 based econazole lacquer 51 Addex Pharmaceuticals www.addexpharma.com discoverMunsif Khan spokesman 51 intravesical infusion therapy 51 REVLIMID lenalidomide 51 USP Tablets PEPCID 51 Etanercept 51 neurogenic orthostatic hypotension 51 investigational antiplatelet agent 51 XIAFLEX ™ 51 factor TNF receptor 51 phase IIb clinical 51 highly selective adenosine 51 diagnosed glioblastoma 51 P#X# antagonist 51 Altera Nebulizer System 51 candidate TNFerade biologic 51 multigene expression test 51 PDE4 inhibitor 51 inhibits angiogenesis 51 Arimoclomol 51 Zarnestra 51 Pirfenidone 51 CD4 monoclonal antibody 51 Vilazodone 51 5 fluorouracil leucovorin 51 sulfonylhydrazine class 51 include Altastaph TM 51 novel immunomodulatory 51 visilizumab 51 Hedgehog Pathway Inhibitor 51 Tofacitinib 51 HepaGam B 51 Nexavar ® 51 novel synthetic PEGylated 51 PGL# 51 TRANSDUR Sufentanil 51 Onco TCS 51 neovascular age 51 oral antiviral 51 mTOR inhibitor 51 TYZEKA 51 Additionally Soligenix 51 Elotuzumab 51 Aurexis 51 Exocrine Pancreatic Insufficiency EPI 51 Romiplostim 51 Metformin GR 51 6R BH4 51 refractory APL 51 long acting muscarinic 51 injectable formulation 51 VivaGel TM 51 Abiraterone acetate 51 development diagnostics combinatorial 51 HCV protease inhibitors 51 Nexavar tablets 51 SERMs 51 sNDAs 51 Cloretazine ® 51 Xyntha 51 CCR9 antagonist 51 immune modulating 51 NTDDS 51 lorvotuzumab mertansine 51 intravitreal insert 51 SYCREST 51 Somatuline Autogel 51 Government Qualifying Therapeutic 51 developing biomedical countermeasures 51 genomics proteomics biosensors 51 Fc fusion protein 51 Etravirine 50 BOARD SAYS 50 opioid receptor antagonist 50 Sebivo 50 promising anticancer 50 candidate AQ4N 50 Traficet EN 50 fosbretabulin 50 PEGylated interferon 50 personalized dendritic 50 Civacir 50 antisense drug 50 LHRH antagonist 50 RoACTEMRA 50 HGS ETR1 mapatumumab 50 granted Orphan Designation 50 post operative ileus 50 Vidaza ® 50 #D#C# 50 Aryplase 50 PRTX 50 MGN# 50 Firdapse ™ amifampridine phosphate 50 LUVENIQ 50 seliciclib CYC# 50 HIV protease inhibitor 50 AEG# 50 relapsing multiple sclerosis 50 treats acute lymphoblastic 50 BEMA TM Fentanyl 50 Phase IIb clinical trials 50 active AKT inhibitor 50 SAR# [004] 50 therapeutic monoclonal antibody 50 Clolar ® 50 pan genotypic 50 RECOTHROM ® 50 thymalfasin 50 REMOXY ® 50 hypereosinophilic syndrome 50 Biopharmaceuticals AG 50 Tasimelteon 50 Nabi HB Intravenous 50 non nucleoside polymerase 50 non alcoholic steatohepatitis 50 FACTIVE R gemifloxacin 50 diabetic neuropathic pain 50 ZEFTERA TM Zevtera TM 50 MTP inhibitors 50 Phenoptin 50 Darunavir 50 therapeutically beneficial 50 herpetic keratitis 50 oral cladribine 50 Talabostat 50 fluorinated carbohydrate mimics 50 intranasal insulin product 50 Carfilzomib 50 R sipuleucel T 50 Arcalyst 50 PHX# 50 system vaporizes unformulated 50 OSI Tarceva 50 patented probiotic bacteria 50 Lenalidomide 50 omacetaxine mepesuccinate 50 novel proprietary KL4 50 Receives Positive Opinion 50 HepeX B 50 R pegaptanib sodium 50 rheumatoid arthritis psoriatic arthritis 50 evaluating intravenous picoplatin 50 subcutaneously administered 50 5 HT2A serotonin 50 Vitamin D analogue 50 designated Restanza 50 Evoltra ® 50 IMA# 50 Pradefovir 50 Ganite R 50 Tyrima 50 Demonstrated Significant 50 targets Galectin receptors 50 Eltrombopag 50 Fludara ® 50 Zalypsis 50 JAK3 inhibitor 50 Surfaxin LS 50 Leukine ® 50 Cinryze TM maintaining 50 products Oncaspar ® 50 Allovectin 7 50 Raptiva ® 50 GRNOPC1 contains 50 Taxanes 50 etanercept Enbrel 50 orphan designation 50 London AiM GLPG 50 PrevOnco ™ 50 developed preclinically 50 immune modulators 50 Campath ® 50 drug ISA# 50 Zenpep 50 potent topoisomerase II 50 OvaRex R 50 XL# XL# XL# XL# 50 Monotherapy 50 reformulates existing FDA 50 Everolimus 50 folate analogue metabolic 50 nilotinib Tasigna ® 50 Fabry Disease 50 CEQ# 50 Lixivaptan 50 fostamatinib 50 REBETOL combination therapy 50 PORxin TM 50 novel oral anticoagulant 50 Tocilizumab 50 Ceflatonin 50 Xyrem ® 50 ATryn ® 50 Cloretazine 50 candidate Zemiva 50 GMX# 50 Curaxins 50 VISICOL R 50 self affirmed GRAS 50 Kit CD# positive 50 selective inverse agonist 50 CERVARIX R 50 inception POZEN 49 OPi 49 NeutroPhase TM 49 biocompatible shelf stable 49 Golimumab 49 Solazed 49 Ganite ® 49 lyophilized formulations 49 IMiDs 49 human IgG2 monoclonal 49 human antithrombin 49 Soliris TM eculizumab 49 diagnosed Glioblastoma multiforme 49 selective angiogenic kinase inhibitor 49 ENZON 49 DPX Survivac 49 opioid induced bowel dysfunction 49 Ultra Midcap# Proshares 49 anti secretory 49 Jet Management EJM 49 Junovan TM 49 Miraxion Amarin lead 49 Brentuximab vedotin 49 orally administered immunomodulatory 49 dihydrofolate reductase 49 VEGFR2 inhibitor 49 DURECT proprietary 49 Atrasentan 49 oral ferric iron 49 Mipomersen 49 ONCASPAR 49 Raptiva R 49 Orphan designation 49 Genasense ® 49 Zalbin 49 Humira adalimumab 49 Extended Release Capsules 49 Vicinium TM 49 defensin mimetic antibiotic 49 topoisomerase II inhibitor 49 Unit Dose Budesonide 49 Kevetrin TM 49 rFVIIIFc 49 Oracea ® 49 Pazopanib 49 Roche PEGASYS R 49 estradiol transdermal spray 49 Revimmune TM 49 containing active oxychlorine 49 Germany FSE SCH 49 pegylated interferon peg IFN 49 Adentri 49 BioNeutral antimicrobial formulations 49 romazarit 49 Onconase 49 YONDELIS R 49 induces apoptosis 49 Cx# [002] 49 COMPLETE INVESTMENT PROGRAM 49 severe hypercholesterolemia 49 ELND# 49 Proxinium TM 49 Aganocide 49 Ostarine ™ 49 Modrenal R 49 diagnosed GBM 49 injectable enzyme 49 adrenergic regulation 49 NeoLipid R 49 oral transmucosal 49 candidate KRN# 49 novel anticancer 49 Ciclesonide 49 NICOSAN ™ 49 Keppra ® levetiracetam 49 Tramadol ER 49 systemic immunosuppressive drugs 49 CIMZIA r 49 ocrelizumab 49 psoralen plus ultraviolet 49 RNAi therapeutic targeting 49 Prosaptide 49 sapacitabine CYC# 49 Preotact 49 opioid induced constipation 49 tumor vascular disrupting 49 Luveniq 49 Firazyr 49 gemifloxacin 49 Laquinimod 49 Perifosine 49 Medicinal Products EMEA 49 photoprotective drug 49 trastuzumab DM1 T DM1 49 Abstral ® 49 octreotide implant 49 cyclin dependent kinase inhibitor 49 alvespimycin 49 TELINTRA 49 CONBRIZA 49 oral iron chelator 49 nasal decolonization 49 oral ridaforolimus 49 Neurodex 49 XmAb ® 49 Nitoman 49 Tykhe Capital Llc 49 lipid particles SNALP 49 Biologic License Application BLA 49 alvimopan 49 Pancreate 49 ZFP Therapeutics 49 Thrombin topical Recombinant 49 small molecule defensin 49 refractory acute promyelocytic 49 Novasome ® 49 IRX 2 49 Soliris eculizumab 49 clinically validated 49 tetrabenazine 49 SNT MC# 49 KIACTA ™ 49 Micromet proprietary BiTE 49 polymer platinate 49 HuMax CD4 49 rxRNA 49 autoimmune indications 49 afamelanotide 49 Plicera 49 Adecatumumab 49 certain protein tyrosine 49 Phase #b/#a trial 49 Sprycel dasatinib 49 vaccine GRNVAC1 49 purinergic receptors P#X# 49 non personalized allogeneic 49 Adagen 49 successfully commercialize Iluvien 49 TSX VENTURE YEL FRANKFURT 49 Factor Receptor 49 OLIGON technology 49 Rituxan rituximab 49 approved successor Simponi 49 renin inhibition promising 48 assigned PDUFA 48 advanced carcinoid 48 5 HT2C 48 paclitaxel Taxol ® 48 chronic idiopathic thrombocytopenic purpura 48 BioNumerik 48 Telavancin 48 Thalidomide Pharmion #mg 48 OPAXIO TM 48 Octreolin 48 COLAL PRED ® 48 selectively inhibited 48 Sanvar R 48 antifungals malachite green 48 ENVIRONMENTAL ASSESSMENT 48 chemotherapy induced neutropenia 48 tamibarotene 48 RAPTIVA 48 Ridaforolimus 48 Epothilones 48 Exenatide LAR 48 Nimotuzumab 48 biotherapeutic drugs 48 MILEY CYRUS CYRUS 48 submitted Marketing Authorization 48 ONGLYZA ™ 48 Alemtuzumab 48 immunotherapeutic vaccine 48 International LAB Pharma 48 nasal calcitonin product 48 Dalbavancin 48 next generation URAT1 48 Intravenous CP 48 SUMAVEL 48 Lixisenatide 48 include VALSTAR TM 48 IBS C 48 MEK inhibitor 48 R adalimumab 48 NurOwn 48 AGS PSCA 48 #L Sterilizer 48 OLEPTRO ™ 48 Vascular Wrap TM 48 gefitinib Iressa 48 Ceragenin ™ 48 biomarkers predictive 48 Amrubicin 48 candidate epratuzumab 48 Aloxi R 48 ZOLINZA 48 prodrug 48 developing TB4 48 Saxagliptin 48 potently inhibited 48 ATryn R 48 relapsed multiple myeloma 48 reverse transcriptase inhibitors 48 Myolimus 48 Recommends Approval 48 Vertex telaprevir 48 rNAPc2 48 orally disintegrating 48 ProMune 48 REMOXY NDA 48 GRALISE 48 relapsed refractory multiple myeloma 48 supplemental Biologics License Application 48 Cinryze ™ 48 factors ZFP TF 48 administered orally 48 BCR ABL inhibitors 48 relapsing forms 48 JAK1 48 cutaneous T cell 48 treat atrial flutter 48 epothilone 48 Rebif interferon beta 1a 48 Morquio 48 RECOTHROM R 48 gastrointestinal disorders characterized 48 Zavesca r 48 anionic backbone 48 Syncria 48 Ixempra 48 ZADAXIN ® 48 Gleevec imatinib mesylate 48 Azacitidine 48 Campath alemtuzumab 48 chronic eosinophilic leukemia 48 Ceflatonin ® 48 refractory Hodgkin lymphoma 48 eprodisate Fibrillex TM 48 TKM ApoB 48 pancreatic insufficiency 48 Dual Path 48 Tasigna nilotinib 48 CIP TRAMADOL ER 48 mifamurtide 48 YONDELIS 48 read Palintologist 48 Positive Opinion 48 registrational trial 48 anti EGFR antibody 48 Icatibant 48 LUCASSIN 48 Linaclotide 48 experimental nucleic acids 48 TACI Ig 48 Marketing Authorisation Application 48 volociximab 48 vilazodone 48 nasal antihistamine 48 CG# [003] 48 intravenous AAT 48 guanylate cyclase type 48 Actemra tocilizumab 48 potent suppressor 48 Anavex #-# 48 pain palliation 48 CDP# 48 Anthrax Toxin 48 Excellarate 48 PDUFA Prescription Drug 48 Maxy G# 48 candidate Trofex TM 48 EP #R 48 small molecule tyrosine 48 Noxafil 48 MyVax R 48 ANTEGREN 48 SANDS ® 48 calcitonin salmon nasal spray 48 TolerRx 47 tanespimycin 47 hepatoprotective agent 47 Jevtana 47 Solulin 47 Sphingomab 47 using Innocoll proprietary 47 subependymal giant cell 47 ATL# [001] 47 anti JCV antibody 47 BioFocus DPI Galapagos 47 PhiloGene 47 Zolinza 47 Riversource Large Cap 47 KL4 Surfactant 47 molecular chaperone regulation 47 Zerenex 47 ARE PROVIDED ON 47 Orapred ODT 47 Achieves Prestigious 47 NOXAFIL 47 Risperidone Oral Solution 47 THEIR ENTIRE INVESTMENT 47 Cryopyrin Associated Periodic Syndromes 47 rhFVIIa 47 ARIKACE ™ 47 OMP designation 47 novel cardiac myosin 47 diagnosed glioblastoma multiforme 47 TEMODAL 47 Reclast zoledronic acid 47 QRxPharma 47 Protectans 47 Raf MEK ERK 47 proprietary MSCRAMM protein 47 recombinant PSMA vaccine 47 TORISEL 47 Nasulin ™ 47 vascular disrupting agent 47 NOVARTIS 47 Affymetrix GeneChip ® 47 Behcet uveitis 47 sorafenib tablets small 47 DPP4 inhibitor 47 PrevOnco 47 Alimta pemetrexed 47 Ligand proprietary 47 CombinatoRx proprietary 47 BAY #-# 47 virosome 47 MAXY G# 47 unpartnered guanosine nucleotide analog 47 preferentially localized 47 OHR/AVR# 47 specific lectin receptors 47 ADVEXIN p# therapy 47 terlipressin 47 Co Receptor Tropism 47 Vandetanib 47 liposomal delivery 47 AcryMed technologies 47 ixabepilone 47 prostanoid 47 combine recombinant protein 47 Revlimid lenalidomide 47 selective endothelin 47 maximal tolerated 47 Increlex TM 47 software rapidly identif 47 Ceplene TM 47 prolific Slave Craton 47 Nexavar sorafenib 47 PURPOSE OF SAFE HARBOR 47 PharmFilm ® 47 novel bactericidal 47 AA amyloidosis 47 Telzir 47 atacicept 47 Plenaxis TM 47 albinterferon alfa 2b 47 HuMax EGFr 47 Sylvie Gregoire President 47 FIRMAGON R 47 CCR5 inhibitor 47 Locked Nucleic Acid LNA 47 NerPharMa 47 preclinical pharmacology 47 gluteal injection 47 Azedra ™ 47 HuCAL GOLD R 47 Taxotere docetaxel 47 Captisol ® 47 HuCNS SC ® 47 Cleviprex TM clevidipine 47 neurology metabolism 47 Australian Therapeutic Goods 47 macular edema secondary 47 cytochrome P# #A# 47 Idiopathic Pulmonary Fibrosis 47 Evamist TM 47 peginesatide 47 Factor Xa inhibitor 47 radioimmunotherapeutic agent 47 TIGRIS R 47 eprodisate KIACTA TM 47 Remicade infliximab 47 Rotarix ® 47 Torisel